Back to speakers




City: Milan

Institution: Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan


Biography of Pietro LAMPERTICO

Professor Pietro Lampertico is Associate Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division, Head of the “A.M. e A. Migliavacca” Center for Liver Disease at the Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

A 1986 graduate of the State University of Milan with degrees in medicine and surgery, Professor Lampertico completed his postdoctoral research in the Department of Experimental Pathology at Tulane University in New Orleans, USA. Upon his return to Milan, he completed specialisations in liver diseases and internal medicine. He received his PhD in clinical methodology from the University of Milan in 1998. In the Gastroenterology Unit, Professor Lampertico is primarily involved in the clinical management of chronic viral hepatitis outpatients, particularly those with CHB. His research interests include the treatment of patients with chronic hepatitis/cirrhosis due to HBV, the long-term outcome of cirrhotic patients undergoing antiviral treatment, and the diagnosis and management of antiviral resistance to oral nucleos(t)ide analogues. Since November 2016, as Director of the Gastreonterology and Hepatology Division, he overlooks all the medical and scientific activities in the field of liver disease.

Professor Lampertico is currently a reviewer for Lancet, Gastroenterology, Hepatology, Gut, Journal of Hepatology and other top ranked journals. He is a member of AASLD, EASL and AISF and serves in the Editorial Board of prestigious journals.

He has spoken internationally about liver disease, specifically the natural history of HBV and antiviral treatment, and has published several articles and book chapters. He is currently involved in national and international HBV clinical trials.

PHC's participations

Monday, March 27th 2023

Controversy: stop NUCs ? (chairman) -

13th PHC – 2020

Monday, January 13th 2020

How to optimize current therapy with PEG IFN? -

Tuesday, January 14th 2020

LUNCH WORKSHOPS - 2. Management of hepatitis delta in 2020*: Room 243 -

12th PHC – 2019

Tuesday, January 15th 2019

The importance of NUC-Peg IFN combination -

3rd PHC – 2009

Tuesday, January 20th 2009

Why do I treat my patients with nucleos(t)ide analogs ? -

Luncheons - Room 2 -

4th PHC – 2011

Tuesday, January 18th 2011

Why do I treat my patient with pegylated interferon? -

6th PHC – 2013

Tuesday, January 15th 2013

Why do I treat my patient with pegylated IFN? -

Interactive Luncheons - Room 1 (chairman)

7th PHC – 2014

Tuesday, January 14th 2014

Why do I treat my patient with a NUC? -

11th PHC – 2018

Tuesday, January 16th 2018

Is there still a role for interferon ? -

Luncheon Workshops - (chairman)

10th PHC – 2017

Tuesday, January 31st 2017

Long term impact of antiviral therapy (NUCs) -

8th PHC – 2015

Tuesday, January 13th 2015

How do I treat my HBeAg-negative patients? -

9th PHC – 2016

Tuesday, January 12th 2016

Prognosis and management of inactive carriers -